ERBB2 and ductal breast carcinoma in situ: Our peptide-loaded SOMV can be seamlessly and effectively implemented in other neoantigen vaccines, such as the iNeo-Vac-P01 for pancreatic cancer[31], and the HER2-derived MHC I peptide E75 vaccine used in clinical trial for ductal carcinoma in situ [32].